Shared Molecular and Functional Frameworks among Five Complex Human Disorders: A Comparative Study on Interactomes Linked to Susceptibility Genes

Ramesh Menon1,2, Cinthia Farina1,2*
1 Neuroimmunology and Neuromuscular Disorders Unit, Foundation IRCCS Neurological Institute Carlo Besta, Milan, Italy, 2 Institute of Experimental Neurology (INSpE), San Raffaele Scientific Institute, Milan, Italy

Abstract

Background: Genome-wide association studies (gwas) are invaluable in revealing the common variants predisposing to complex human diseases. Yet, until now, the large volumes of data generated from such analyses have not been explored extensively enough to identify the molecular and functional framework hosting the susceptibility genes.

Methodology/Principal Findings: We investigated the relationships among five neurodegenerative and/or autoimmune complex human diseases (Parkinson’s disease-Park, Alzheimer’s disease-Alz, multiple sclerosis-MS, rheumatoid arthritis-RA and Type 1 diabetes-T1D) by characterising the interactomes linked to their gwas-genes. An initial study on the MS interactome indicated that several genes predisposing to the other autoimmune or neurodegenerative disorders may come into contact with it, suggesting that susceptibility to distinct diseases may converge towards common molecular and biological networks. In order to test this hypothesis, we performed pathway enrichment analyses on each disease interactome independently. Several issues related to immune function and growth factor signalling pathways appeared in all autoimmune diseases, and, surprisingly, in Alzheimer’s disease. Furthermore, the paired analyses of disease interactomes revealed significant molecular and functional relatedness among autoimmune diseases, and, unexpectedly, between T1D and Alz.

Conclusions/Significance: The systems biology approach highlighted several known pathogenic processes, indicating that changes in these functions might be driven or sustained by the framework linked to genetic susceptibility. Moreover, the comparative analyses among the five genetic interactomes revealed unexpected genetic relationships, which await further biological validation. Overall, this study outlines the potential of systems biology to uncover links between genetics and pathogenesis of complex human disorders.

Introduction

The aim of genome-wide association studies (gwas) is to discover the common genetic variants associated with susceptibility to complex diseases. In a typical experiment, hundreds of thousands of markers are tested simultaneously in cases and controls, and the allelic frequencies of each marker in the two groups are compared, so that the contribution of single genes to the disease is quantified. However, complex diseases do not originate from changes in single genes, but from the interactions between several genetic and environmental factors. Therefore, the analysis of isolated genes is not overly informative about the biological processes underlying disease and offers limited rationale for the development of novel therapies. Theoretically, reconstruction of the molecular interaction networks linked to gwas-genes by systems biology approaches may help to elucidate the functional consequences related to each susceptibility allele and the combined effects of more genetic variants. The few reports available to date on this issue demonstrated that this approach can identify previously unseen relationships among human diseases at molecular level [1,2].

In this study, we elaborated the genetic interactomes relative to five complex human diseases. Our lab has strong interest in multiple sclerosis (MS), a chronic disorder of the central nervous system presumably of autoimmune etiology, characterized by inflammation of the white matter, demyelination and neurodegeneration [3]. Initially, we reconstructed the MS interactome and searched for interactions with genes predisposing to either neurodegenerative (Parkinson’s disease Park, Alzheimer’s disease Alz) or autoimmune (Type 1 diabetes T1D, Rheumatoid Arthritis RA) disorders. Then, disease interactomes of all five disorders were analyzed at the functional level by independent pathway enrichment studies. Finally, paired comparisons elucidated relatedness among the diseases. Interestingly, the shift from single genes to molecular frameworks via system biology unraveled novel functional relationships among the five complex diseases.
Results

Link between the MS interactome and the genes predisposing to other neurodegenerative or autoimmune diseases

Initially we identified the susceptibility genes that were linked to MS and to other neurodegenerative (Park, Alz) or autoimmune (T1D, RA) disorders. We utilized results from 39 published genome-wide association studies on these five human diseases available in the GWAS catalog [4] and found genetic mutations in 179 genes passing the statistical significance threshold of $10^{-5}$ (Table 1). There were 6 studies available for MS, Park and RA, 8 for T1D, and 13 for Alz (Table S1). Notably, the number of studies carried out for each disease did not seem to influence the total number of disease-associated genes. For instance, despite the highest number of genome-wide association studies performed for Alz, the total number of susceptibility genes reported was the lowest among the five diseases. The ratios between the number of the reported genes and the number of studies in each disease accounted for this observation (Table 1). Interestingly, MS displayed the highest number of susceptibility genes and the highest ratio, suggesting a greater genetic heterogeneity in MS than in the other four diseases. Then, as a first step towards the definition of the genetic network underlying these five diseases, we reconstructed the MS genetic interactome and checked possible links with the genes predisposing to the other neurodegenerative or autoimmune diseases. Using the VisANT tool we derived 376 first-degree interacting partners for the 54 MS gwas-genes. Among these MS interactors, 141 were connected with at least one among 17 T1D, 11 RA, and 10 Park or Alz gwas-genes (Figure 1A and Table S2). Notably, 4 MS interactors were RA (HLA-DQA1, TRAF1) or T1D (IL2, PTPN11) gwas-genes themselves. It was also evident that several gwas-genes could come into contact with two or more MS interactors (Figure 1A), and that 24 MS interactors were connected with both neurodegenerative and autoimmune genes (red nodes in Figure 1A), including the PTPN11 gene.

Now, the analysis of disease relatedness with MS is more effective when considering the genetic interactome rather than direct interactions at the gwas-gene level. In fact, no interactions existed between gwas-genes predisposing to MS and Alz, for example, but there were several shared interactions within the genetic interactomes linked to (but not including) the respective gwas-genes (Figure 1B). Therefore, the introduction of first-degree interactors in the definition of a disease-related molecular framework may lead to the discovery of relatedness among distinct complex disorders.

Molecular relatedness among autoimmune and neurodegenerative genetic interactomes

To perform a global comparative analysis among autoimmune and neurodegenerative genetic interactomes, we derived a list of interacting partners for each gwas-geneset (Table 2, Table S3). As expected, the number of interactors was higher in MS and T1D, due to the more abundant number of reported gwas-genes. However, when normalizing the number of interactors to the total number of gwas-genes in each disease, RA reported the highest

---

Table 1. Summary of gwas data.

|          | MS | Park | Alz | T1D | RA | Total |
|----------|----|------|-----|-----|----|-------|
| No. of studies | 6  | 6    | 13  | 8   | 6  | 39    |
| Unique genes    | 54 | 35   | 17  | 52  | 21 | 179   |
| Gene/study ratio | 9  | 5.83 | 1.30| 6.50| 3.50| 4.58  |

doi:10.1371/journal.pone.0018660.t001

Figure 1. Relationship between MS interactome and gwas genes relative to other diseases. A. MS interactors shared by genes predisposing to neurodegenerative (green) and/or autoimmune (pink) diseases. Blue nodes indicate the MS interactors contacted by either neurodegenerative or autoimmune susceptibility genes. Red nodes indicate the MS interactors contacted by both neurodegenerative and autoimmune susceptibility genes. Note that four MS interactors are present among the T1D or RA gwas-genes. B. Comparison between MS and Alz at gwas-gene and genetic interactome levels. Despite the absence of a direct interaction at gwas level, shared molecular networks appear in the genetic interactomes (green section).

doi:10.1371/journal.pone.0018660.g001
ratio among the five diseases, indicating that at least some of the RA susceptibility genes were highly interactive. In contrast, Park displayed the lowest interactor/gene ratio, despite the discrete number of described gwas-genes. In order to identify the biological themes embedded in each interactome, we used the ToppGene suite, an online tool for functional enrichment analysis. A Bonferroni corrected p-value of 0.05 was used to extract the significant biological pathways reported by three distinct databases (CGAP-BioCarta, KEGG and Panther). The highest number of pathways was reported in T1D followed by MS, RA, Alz and Park respectively (Table S6). Furthermore, we tabulated the shared pathways among diseases and grouped them according to the database in seven main categories: Growth factor/Hormone signaling, Innate/Adaptive immunity, Cell cycle and apoptosis, Cancer, Adhesion, Host response and Other (Figure 3). The combined statistical significance of the pathway enrichments is also listed in Figure 3. The majority of shared pathways were categorized in Growth factor/Hormone signaling, followed by Innate/Adaptive immunity and Cell cycle and apoptosis.

Table 2. Genetic interactomes for neurodegenerative and/or autoimmune disorders based on VisANT database.

| Genes Interactors | Interactor/gene ratio |
|--------------------|-----------------------|
| Park 35 160        | 4.57                  |
| Alz 17 109         | 6.41                  |
| T1D 52 316         | 6.07                  |
| RA 21 249          | 11.85                 |
| MS 54 376          | 6.96                  |

For paired analyses we multiplied the normalization factors relative to the two diseases [see [materials and methods]], and used the paired normalization factor to optimize the observed/expected ratio of interactor sharing. This resulted in an interactor score for each disease pair (Figure 2). So, if on the one hand the p-values relative to the inter-disease relatedness may reflect the shared interactome among diseases, on the other hand the interactor score might flatten or enhance some of these observations as it corrects for annotation bias. Therefore, both the p-values and the interactor scores have to be considered while interpreting the results. The interactor scores confirmed the close association among disease pairs in the autoimmune group (Figure 2). Surprisingly, the highest scores appeared in Alz-Park and T1D-Alz pairs. Therefore, even after eliminating the possible bias introduced by database annotation, the T1D-Alz pair maintained high association levels.
**Figure 3. Pathways shared among diseases.** Colors refer to the three distinct databases used for the pathway enrichment analysis. The combined p-values for pathway overlap among diseases are given. doi:10.1371/journal.pone.0018660.g003

| Category 1: Growth factor/Hormone signaling | Pathway Description | P-Val* |
|-------------------------------------------|---------------------|--------|
| Alz, T1D, RA | EGF receptor signaling | 6.6E-13 |
| Alz, T1D, RA | FGF signaling | 3.6E-10 |
| Alz, T1D, MS | PDGF signaling | 4.2E-14 |
| T1D, MS | Interleukin signaling | 1.0E-16 |
| T1D, MS | JAK/STAT signaling | 3.6E-06 |
| T1D, RA | PI3 kinase | 1.5E-06 |
| Alz, T1D | Angiogenesis | 1.1E-18 |
| Alz, T1D, RA, MS | ErbB signaling pathway | 3.1E-33 |
| T1D, RA, MS | Adipocytokine signaling pathway | 7.1E-15 |
| T1D, RA | Cytokine-cytokine receptor interaction | 2.4E-07 |
| T1D, MS | Insulin signaling pathway | 1.5E-06 |
| T1D, MS | Jak-STAT signaling pathway | 3.6E-25 |
| RA, MS | MAPK signaling pathway | 1.1E-06 |
| Alz, T1D, MS | EGF Signaling | 8.9E-17 |
| Alz, T1D, MS | EPO Signaling | 1.8E-13 |
| Alz, T1D, MS | IL 6 signaling | 4.1E-06 |
| Alz, T1D, MS | PDGF Signaling | 6.5E-12 |
| Alz, T1D, MS | Signaling of Hepatocyte GF Receptor | 4.3E-12 |
| Alz, T1D, MS | Angiotensin II mediated activation of JNK | 5.7E-08 |
| Alz, T1D, MS | Sprouty regulator of Trk signaling | 9.4E-09 |
| Alz, T1D, MS | Links between Pyk2 and MAP kinases | 1.4E-13 |
| Alz, T1D, MS | Trka Receptor Signaling | 1.7E-09 |
| Alz, T1D, MS | Dynamic Reactive Induced Signaling | 1.1E-07 |
| Park, RA, MS | Ceramide Signaling | 1.1E-12 |
| Park, T1D, MS | Trefoil Factors initiate Mucosal Healing | 3.6E-10 |
| T1D, RA, MS | Chaperones modulate interferon Signaling | 1.5E-07 |
| T1D, RA, MS | Keratinocyte Differentiation | 3.2E-15 |
| Alz, T1D | Nerve growth factor (NGF) | 2.7E-05 |
| Alz, T1D | IGf-1 Signaling | 3.5E-05 |
| Alz, T1D | IL 3 signaling | 1.4E-06 |
| Alz, T1D | Insulin Signaling | 1.1E-04 |
| Alz, T1D | Growth Hormone Signaling | 9.1E-12 |
| T1D, MS | IL 2 signaling | 1.5E-12 |
| T1D, MS | IL 4 signaling | 4.4E-10 |
| T1D, MS | IL-7 Signaling pathway | 3.8E-09 |
| T1D, MS | CBL mediated ligand-induced downregulation of EGF receptors | 5.6E-07 |
| T1D, MS | CXCR4 Signaling | 3.3E-08 |
| T1D, MS | TPO Signaling | 4.3E-10 |
| T1D, MS | Ca signaling by H8B of Hepatitis B virus | 5.2E-05 |
| RA, MS | MAPK kinase Signaling | 8.0E-11 |
| RA, MS | Signal transduction through IL1Ra | 1.3E-05 |
| RA, MS | SODD/TFN1R signaling | 1.3E-11 |
| RA, MS | TNF/STRESS Related Signaling | 2.8E-21 |
| RA, MS | TNFR1 Signaling | 2.4E-12 |
| RA, MS | TNFR2 Signaling | 5.5E-19 |

| Category 2: Innate and adaptive immunity | Pathway Description | P-Val* |
|------------------------------------------|---------------------|--------|
| Alz, T1D, MS | B cell activation | 1.0E-09 |
| Alz, T1D, MS | T cell activation | 1.1E-31 |
| Alz, T1D, RA, MS | B cell receptor signaling pathway | 2.5E-25 |
| Alz, T1D, RA, MS | T cell receptor signaling pathway | 3.3E-38 |
| T1D, RA, MS | Toll-like receptor signaling pathway | 7.2E-13 |

| Category 3: Cell cycle and apoptosis | Pathway Description | P-Val* |
|--------------------------------------|---------------------|--------|
| Park, RA, MS | Apoptosis signaling | 1.0E-34 |
| T1D, RA | p53 | 1.2E-06 |
| Alz, T1D | Apoptosis | 2.8E-28 |
| T1D, RA | Cell cycle | 7.6E-23 |
| Alz, T1D, RA, MS | PTEN dependent cell cycle arrest and apoptosis | 9.7E-15 |
| Alz, T1D, MS | Inhibition of Cellular Proliferation by Gleevec | 2.4E-11 |
| T1D, RA, MS | Telomerase, Telomerase, Aging, Immortality | 1.2E-12 |
| T1D, RA | Cyclins and Cell Cycle Regulation | 1.0E-16 |
| T1D, RA | Influence of Ras and Rho proteins on G1 to S Transition | 6.5E-14 |

| Category 4: Cancer | Pathway Description | P-Val* |
|-------------------|---------------------|--------|
| Park, Alz, T1D, MS | Colorectal cancer | 7.1E-10 |
| Alz, T1D, MS | Prostate cancer | 3.1E-19 |
| Alz, T1D, RA, MS | Pancreatic cancer | 4.4E-24 |
| Alz, T1D, RA, MS | Pathways in cancer | 1.1E-46 |
| Alz, T1D, RA, MS | Chronic myeloid leukemia | 8.6E-49 |
| T1D, RA, MS | Acute myeloid leukemia | 7.7E-13 |
| T1D, RA, MS | Small cell lung cancer | 4.8E-26 |
| Abz, T1D, RA | Glioma | 1.0E-18 |
| Abz, T1D, RA | Non-small cell lung cancer | 5.9E-17 |

| Category 5: Adhesion | Pathway Description | P-Val* |
|---------------------|---------------------|--------|
| Park, T1D, RA, MS | Focal adhesion | 8.8E-14 |
| Alz, T1D, MS | Adherens junction | 1.9E-08 |
| Park, Alz, T1D, MS | Integrin Signaling | 6.7E-20 |

| Category 6: Host response | Pathway Description | P-Val* |
|---------------------------|---------------------|--------|
| Alz, RA, MS | Epithelial cell signaling in H. pylori infection | 8.2E-11 |
| Park, MS | Pathogenic E. coli infection – EHEC | 6.3E-09 |
| Park, MS | Pathogenic E. coli infection – EPEC | 6.3E-09 |

| Category 7: Other | Pathway Description | P-Val* |
|-------------------|---------------------|--------|
| Park, RA | Parkinson’s disease | 1.0E-13 |

* Combined p-values by Fisher’s method.
while categories like Cancer, Host response and Other appeared in single databases.

In the Growth factor/Hormone signaling category, Panther indicated EGF, FGF and PDGF signaling pathways as shared by three diseases, Alz and T1D with MS or RA. The other pathways were shared exclusively by autoimmune diseases, with the exception of Angiogenesis that appeared both in T1D and Alz. In contrast to Panther, KEGG evidenced predominant pathway sharing among autoimmune disorders, except for the ErbB signaling present in Alz and MS in the three autoimmune diseases. CGAP-BioCarta exposed high concordances among Alz, T1D and MS. There were 10 pathways shared exclusively by these three diseases, among which EGF signaling and PDGF signaling were already reported by the Panther database. Many of the pathways common to these trios were related to tyrosine kinase signaling, such as Trka receptor signaling and Sprouty regulation of tyrosine kinases. Another remarkable observation was the sharing of the NFè pathway by MS and Alz. IGF-1 signaling, IL3 signaling, Insulin signaling and Growth hormone signaling pathways were shared exclusively by T1D and Alz. In addition, Park shared only three pathways with the autoimmune diseases, namely Ceramide signaling, TGF幻想 factors initiate mucosal signaling and Phosphoinositides and their downstream targets. Overall, pathways shared by the five diseases in the Growth factor/Hormone signaling category portrayed an undisputable association within the autoimmune group with the predominant presence of T1D. It also revealed that several biological themes related to tyrosine kinase signaling were shared among Alz, T1D and MS. Most unexpectedly, the analysis exposed numerous growth factor related pathways common to T1D and Alz.

The second category Innate and adaptive immunity contained 20 pathways derived from the three pathway databases. Although expected for autoimmune diseases, consistent sharing of immunity related pathways was also found in Alz. For example, pathways related to B and T cell activation appeared in all databases as shared by T1D, RA, MS and Alz. Furthermore, in the KEGG database Alz and T1D exclusively shared the Fc epsilon RI signaling pathway and Natural killer cell mediated cytotoxicity pathway, whereas CGAP-BioCarta emphasized predominant pathway sharing between MS and RA.

In the third category, Cell cycle and apoptosis, Panther and KEGG contributed with 2 pathways each, and Park shared the Apoptosis signaling pathway with RA and MS. Among the CGAP-BioCarta results, Alz shared 3 pathways with autoimmune diseases, while 4 pathways were shared exclusively by T1D-RA or RA-MS disease pairs.

The fourth category contained pathways derived from the KEGG database related to Cancer. It resulted that many genes appearing in autoimmune and/or neurodegenerative interactomes played a role in cancer related pathways.

In the fifth category (named Adhesion), the Focal adhesion pathway (KEGG) was common to Park and the autoimmune group and the Integrin signaling pathway (CGAP-BioCarta) was shared among neurodegenerative disorders and T1D. In addition, the Adherens junction pathway in KEGG was shared among Alz, T1D and MS.

The sixth category contained pathways related to Host response, which was reported exclusively by the KEGG database. Park and MS shared two pathways related to E. coli infection, and the autoimmune diseases shared the Epithelial cell signaling in Helicobacter pylori infection pathway. Lastly, the category Other contained the Parkinson’s pathway reported by Panther, which was common to Park and RA.

Overall, pathway analysis revealed predominant sharing of functions among autoimmune diseases. Moreover, many of these pathways appeared also in Alz, which was associated with T1D in most cases.

Quantitative analysis of functional relatedness among neurodegenerative and autoimmune interactomes

We tabulated the shared pathways for all disease pairs (Table S7) and quantified the significance of observed pathway overlaps by performing a hypergeometric test for each database separately (Figure 4A). According to Panther, the most significant pathway overlap was in the T1D-Alz pair (P = 2.10E-07), followed by the T1D-RA (P = 1.48E-05) and the RA-Alz (P = 8.69E-05). The MS-Park pair displayed no significant pathway overlap (P = 0.184).

Among the KEGG results, the most highly significant pathway overlap was between MS and RA (P = 1.03E-13), followed by T1D-RA (P = 5.12E-12), T1D-Alz (P = 5.91E-11), MS-T1D (P = 8.58E-10) etc. Yet, the analysis revealed that pathway overlaps with Park could be due to chance, except for the MS-Park pair (P = 5.44E-09). Finally, the CGAP-BioCarta analysis recognized T1D-Alz as the most significant association (P = 3.71E-12), followed by MS-RA (P = 1.60E-11), MS-T1D (P = 2.16E-09), MS-Alz (P = 1.60E-08) etc. To summarize, the p-values based on KEGG and CGAP-BioCarta databases were more significant among the disease pairs in the autoimmune group, especially MS-RA. Moreover, on the basis of consistent statistical results in all the three databases, the T1D-Alz pair can be considered as the most significant disease pair in the context of shared pathways.
Theoretically, pathway sharing was partly anticipated as consistent interactor sharing was present in several disease pairs. Clearly, the more interactors were shared, the more common pathways were expected. We critically evaluated this issue and measured the Pearson’s correlation between the interactors and the pathways (as reported by the three databases together) shared among the disease pairs. Consistently, we observed that the number of shared pathways was proportional to the number of shared interactors in most cases (Figure 4B). However, the Alz pairs with autoimmune diseases were not following this trend. The overall Pearson’s correlation coefficient was 0.79, which increased remarkably to 0.95 when Alz-autoimmune disease pairs were excluded. These observations demonstrate that the number of shared biological pathways among Alz and autoimmune diseases is higher than expected on the basis of interactor sharing.

Finally, we ranked the associations among diseases based on the statistical significance of shared pathways in each database (Table S6). Scores starting from 1 were assigned from the highest significant association to the lowest. Those with insignificant p-values were assigned the rank 10. Then, we derived the cumulative ranks for each disease pair by summing their ranks in the three databases. As expected, T1D-Alz pair had the highest rank, followed by the autoimmune disease pairs MS-RA and T1D-RA, and then by MS-Alz and RA-Alz. All Park pairs scored very low. These results were depicted in Figure 5 displaying a network summary of relationships among the five diseases.

Altogether, the relationships among diseases identified at the level of molecular interactions were found to be sustained at the level of biological pathways, especially among autoimmune diseases. Surprisingly, the same approaches evidenced strong relatedness between Type 1 diabetes and Alzheimer’s disease.

**Discussion**

The reconstruction of the molecular framework hosting genetic variants associated with susceptibility to a complex human disorder has the potential to reveal the biological mechanisms underlying that disease and to highlight similarities with other diseases. Here we made a cross-disease comparison of autoimmune (T1D, RA) and neurodegenerative diseases (Park, Alz) starting from the point of view of MS, as it presents both autoimmune and neurodegenerative facets [3]. Indeed, several nodes in the MS interactome interacted with the susceptibility genes of the other four diseases, with a subset of MS interactors making contact with both autoimmune and neurodegenerative gwas-genes. These observations indicate that MS offers a framework that, to a certain extent, can be shared by other diseases. This is partly due to the fact that genetic susceptibility to autoimmune disorders may be driven by variations in some common genes [5,6]. In this regard, two scenarios have been demonstrated. In the first case, the same variant may be involved in susceptibility to distinct diseases. For instance, genetic variation in the CLEC16A gene is associated with MS as well as T1D in the Sardinian population [7]. In the second case, distinct variants in the same gene predispose to distinct diseases, i.e. polymorphisms in the IL2RA gene linked to MS or T1D susceptibility are different [8,9].

Previous studies have shown that molecular relatedness between distinct diseases may be found when searching for direct relationships among gwas-genes [10,11] and that the analysis of first-degree interactors may also lead to similar observations[1,2]. However, the advantage of the second approach compared to the first one has never been specifically addressed. Our study shows that the analysis of first-degree genetic interactomes may highlight shared molecular frameworks undetectable at the gwas-gene level. In fact, even when no interactions exist between gwas-genes, several shared interactions may be found when considering the genetic interactomes.

Furthermore, we elucidated the interactors linked to the gwas-genes in all five diseases and the pathway enriched in each disease-related interactome using the ToppGene suite. This tool contains a meta-database of annotated pathway databases such as Panther, KEGG, and CGAP-BioCarta. As the level of annotation and the number of genes related to a pathway may vary among databases [12], the outputs were not pooled but shown in relation to each database. Although a few previous studies revealed enriched biological pathways related to susceptibility genes in several complex human disorders, including MS [10,13–15], no information was available on pathways emerging from the global genetic framework. In contrast, our study ascertained such issue in multiple sclerosis as well as in four additional autoimmune or neurodegenerative disorders. Independent pathway analyses demonstrated several commonalities among distinct genetic interactomes. Numerous immune related pathways were enriched in autoimmune interactomes. This result was expected as many of the susceptibility genes in RA, T1D and MS were immune related. Notably, the pathways B-cell activation and T-cell activation appeared in all autoimmune diseases. It is well known that both arms of adaptive immunity greatly contribute to autoimmunity. Our data suggest that the processes leading to alterations in immune tolerance may be caused or sustained by the genetic framework, and, hence, support the rationale for therapeutical approaches.
targeting T and B lymphocytes in autoimmune disorders. Surprisingly, the same pathways appeared in Alzheimer’s disease. The role of adaptive immunity in Alz so far remains under-explored, however some studies suggest altered T cell phenotypes and responses in such patients (reviewed by [16]). Interestingly, regular use of anti-inflammatory drugs reduces the odds of developing Alz [17,19]. Our observation that the Alz genetic framework may have an impact on immune function questions the classical distinction between inflammatory and non-inflammatory diseases and supports the hypothesis that, even though the primary insult is not inflammation but neurodegeneration, immunological pathways play a role in the etiopathogenesis of Alzheimer’s disease [19].

Most of the enriched pathways appeared in the category Growth factor/Hormone signaling consistently among the three pathway sources. Panther and CGAP-BioCarta reported the EGF related pathway as enriched in Alz, T1D and RA or MS respectively, while KEGG highlighted the ErbB signaling pathway in all four diseases. EGF receptor belongs to the ErbB gene family. Interestingly, EGF is decreased in liquor from multiple sclerosis patients [20], while increased in the synovial fluid of RA patients, where it may regulate the inflammatory process [21]. Moreover, EGF promotes the release of amyloid precursor protein (APP) [22], indicating that it might support amyloidogenesis in Alz. Finally, downregulation of the EGF receptor signaling in pancreatic islets causes diabetes [23]. Our data suggest that the involvement of the EGF pathway in the pathogenesis of various complex human disorders may be genetically determined. The FGF signaling pathway appeared in two databases as enriched in T1D and Alz. Interestingly, biological evidence links alterations in this pathway to the two diseases, e.g. attenuation of FGF signaling in mouse beta cells leads to diabetes [24], and aFGF levels in liquor are increased in Alzheimer’s patients [25]. Insulin related pathways were also enriched in T1D and Alz interactomes. Obviously, the major defect in T1D is insulin deficiency caused by the autoimmune attack against pancreatic β-cells. Accumulating evidences indicate that alterations in insulin signaling may contribute to Alz pathology (reviewed in [26]). Moreover, tau phosphorylation is increased in diabetic animals [27], and mice with combined APP overexpression and diabetes show exacerbated histological features of Alz [28]. Another interesting overlap is the angiogenesis pathway shared exclusively between Alz and T1D, especially if interpreted in relation to blood brain barrier dysfunction due to increased vascular permeability induced by hyperglycemia [29]. Further sharing of Growth factor/Hormone signaling pathways between Alz and T1D strongly supports the hypothesis of a genetic and functional link between these two disorders.

CGAP-BioCarta highlighted TNF related pathways both in RA and MS genetic interactomes. TNF is an inflammatory mediator clearly involved in the RA and MS pathology [30,31]. Intriguingly, various biological compounds targeting TNF resulted effective in RA treatment [32], while detrimental in multiple sclerosis [33], indicating that TNF related pathways may play a dual role in autoimmune diseases.

The Cell cycle and apoptosis category was almost dedicated to autoimmune diseases. Such pathways regulate induction of immune tolerance and, indeed, changes in the balance between cell proliferation and death may lead to autoimmunity [34,35]. The same processes may be altered in neoplastic cells. Cancer related pathways also consistently appeared enriched in the KEGG database. Overall, our data indicate that the genetic framework predisposing to complex human disorders may contribute to changes in these basic cellular functions.

The paired comparisons of genetic interactomes allowed measuring the degree of relatedness among the five disorders. Sharing of interactors and pathways was highly significant among the autoimmune group. This may be partly explained by the genetic overlap between autoimmune diseases [5,6]. In fact, among all autoimmune gwas-genes analyzed in our study, HLA-DRB1 was associated with MS, T1D and RA, three genes (PTPN22, PRKCQ, CTLA4) were shared between T1D and RA, three (IL2RA, IL7R and CLEC16A) between MS and T1D, and one more (CD40) between MS and RA. However, analyses at the genetic network level also showed that several gwas-genes specific for single pathologies converged at the interactor level, meaning that, although the primary events may differ, the resulting functional cascades may come together and lead to alterations in the same pathways.

The most surprising observation was the strong correlation in the T1D-Alz pair in terms of shared interactome and functions. Moreover, this pair was found highly related by consistent performances in the three distinct pathway databases. Clinical and epidemiological data are available on associations between T1D and Alz. Type 1 (and Type 2) diabetic patients present deficits in numerous cognitive functions [reviewed in [36]] and diabetes is a risk factor for Alz [37]. In addition, biological evidence indicates that dysregulation of insulin metabolism may affect amyloid-β accumulation and degradation [38].

In conclusion, in this article we provided an unprecedented comparison among the genetic interactomes derived from genes predisposing to five complex human disorders. The shift in the network analysis from the gwas-genes to their first-degree interactors made the detection of shared molecules possible even when no interactions were present at the gwas-level. Furthermore, it revealed strong molecular and functional relatedness among autoimmune disorders. For example, the genetic interactomes pertaining to autoimmune diseases converged on numerous routes regarding immunity and growth factor signalling pathways. So, network generation and functional annotation highlighted several known pathogenic processes, indicating that changes in these functions might be driven or sustained by the framework linked to genetic susceptibility. Finally, the same tools underlined several inherent relationships among the five diseases at the level of genetic interactomes and biological pathways which went unnoticed until now. Type 1 diabetes and Alzheimer’s disease were emblematic in this respect, as they appeared the most closely related disorders among all the disease pairs due to the extensive sharing of interactors and functions.

Overall, this study established that the reconstruction of the molecular framework hosting the genetic variants predisposing to complex human disorders can significantly contribute to our understanding of the biological functions linked to susceptibility genes. Many of these in-silico results highly correlate with the present experimental biology evidence, proving the reliability of systems biology tools. Furthermore, the study revealed unexpected genetic relationships, which await further biological validation.

**Materials and Methods**

**Diseases and genetic association data**

We collected genome wide association data related to five human diseases (T1D, RA, Park, Alz and MS) from the GWAS catalog (December 2009 version). The GWAS database is an online resource comprising of all published genome-wide association studies or meta-analyses of them, and provides information regarding the gene, SNP variations and their statistical significance in each study. We retrieved all the genes predisposing to each

![Image](plonelseat.png)
disease with the default critical p-value (10\(^{-05}\)) of the database. The list of genes associated with each disease is summarized in Table 1 and the detailed records about each study such as sample size, journal name, authors, site of polymorphism etc. are summarized in the Table S1.

Interactome analysis
To derive the list of interacting partners of the gwas-genes, we used the VisANT tool (December 2009 version) [39], a web-enabled program for construction, visualization, and analysis of molecular and higher order networks based on functional and physical relations of the gene sets. Further, VisANT retrieves the interaction information from databases such as BIND, MIPS, Biogrid, HPRD and CAGT. The lists of interactors are given in Table S3. The statistical significances for the interactor overlap among disease pairs were calculated using a hypergeometric test. In order to compensate the eventual biases in database annotation, we calculated the interactor score through the normalization of the observed/expected ratio. In the VisANT database there were 95684 interactions among 12888 Homo sapiens genes, resulting in an average of 7.26 interactions per gene (VisANT interaction ratio). This ratio was used for normalization, as follows:

\[
\text{Disease interaction ratio} = \frac{\text{No. of interactions}}{\text{No. of gwas-genes}}.
\]

Normalization factor = Disease interaction ratio/VisANT interaction ratio.

Paired normalization factor = (Disease1 normalization factor) x (Disease2 normalization factor).

Observed = No. of interactors shared within a disease pair.

Expected = (No. of interactors in disease 1/12888) x (No. of interactors in disease2).

Intactor score = (Observed/Expected) x (Paired normalization factor).

Pathway enrichment study
We chose the ToppGene suite for determination of pathways enriched in the genetic interactomes. At the time of analysis, this tool maintained a meta-database of pathway information derived from KEGG (update: June 2009), Panther (update information not available), CGAP-BioCarta (update: August 2009). The analysis was performed with the stringent criteria of Bonferroni corrected p-value cut-off 0.05 in all cases. The combined p-values were calculated for the shared pathways among diseases using Fisher’s method [40].

Supporting Information
Table S1 Detailed records about the studies in the GWAS catalog used in our analyses.
(XLS)
Table S2 Overlap of MS genetic interactome with genes predisposing to other neurodegenerative or autoimmune diseases.
(XLS)
Table S3 List of the gwas genes and their interactors.
(XLS)
Table S4 Shared interactors in disease pairs.
(XLS)
Table S5 Statistical significances for interactor sharing and interactor scores.
(XLS)
Table S6 Statistical significances for pathway sharing and ranking of disease associations.
(XLS)
Table S7 List of shared pathways in disease pairs.
(XLS)

Acknowledgments
We thank Dr. Zhenjun Hu at Boston University for help with the VisANT database.

Author Contributions
Conceived and designed the experiments: RM CF. Performed the experiments: RM. Analyzed the data: RM CF. Wrote the paper: RM CF.

References
1. Barreras F, Chaval S, Holme P, Moblin R, Benson M (2009) Network properties of complex human disease genes identified through genome-wide association studies. PLoS One 4: e8090.
2. Feldman I, Rzhetsky A, Vinko D (2008) Network properties of genes harboring inherited disease mutations. Proc Natl Acad Sci U S A 105: 4323–4328.
3. Trapp BD, Nave KA (2008) Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247–269.
4. Hindlof LA, Sereshropy P, Juninks HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implication of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362–9367.
5. Seldin MF, Amos CI (2009) Shared susceptibility variations in autoimmune diseases: A brief perspective on common issues. Genes Immun 10: 1–4.
6. Zenevitz LA, Abraham C, Flavell RA, Chot JH (2010) Unraveling the genetics of autoimmunity. Cell 140: 791–797.
7. Zoledziewska M, Costa G, Pitzalis M, Cocco E, Melis C, et al. (2009) Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in sarcidina. Genes Immun 10: 15–17.
8. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Saucier S, Lander ES, et al. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851–862.
9. Lowe CE, Cooper JD, Brucki T, Walker NM, Smyth DJ, et al. (2007) Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 39: 1074–1082.
10. Baranzini SE (2009) The genetics of autoimmune disease: A networked perspective. Curr Opin Immunol 21: 596–605.
11. Moskvina V, Craddock N, Holmans P, Nikolov I, Pahlwa JS, et al. (2009) Gene-wide analyses of genome-wide association data sets: Evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 14: 252–260.
12. Huang R, Wallqvist A, Covell DG (2006) Comprehensive analysis of pathway or functionally related gene expression in the national cancer institute’s anticancer screen. Genomics 87: 513–529.
13. Zhong H, Yang X, Kaplan LM, Molony C, Schadt EE (2010) Integrating pathway analysis and genetics of gene expression for genome-wide association studies. Am J Hum Genet 86: 581–591.
14. Li Y, Agarwal P (2009) A pathway-based view of human diseases and disease relationships. PLoS One 4: e4546.
15. Baranzini SE, Galwey NW, Wang J, Khakhakanian P, Lindberg R, et al. (2009) Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 18: 2076–2090.
16. Town T, Tan J, Flavell RA, Mullin M (2005) T-cells in alzheimer’s disease. Neuromolecular Med 7: 255–264.
17. McGeer PL, Schuler M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for alzheimer’s disease: A review of 17 epidemiologic studies. Neurology 47: 425–432.
18. Vlados C, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAID on the development of alzheimer disease. Neurology 70: 1672–1677.
19. Zipp F, Aktas O (2006) The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29: 518–527.
20. Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, et al. (2010) Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res 1353: 64–71.
21. Nah SS, Won HJ, Ha E, Kang I, Cho HY, et al. (2010) Epidermal growth factor increases prostaglandin E2 production via ERK1/2 MAPK and NF-kappaB pathway in fibroblast like synoviocytes from patients with rheumatoid arthritis. Rheumatol Int 30: 443–449.

22. Refolo LM, Salton SR, Anderson JP, Mehta P, Robakis NK (1989) Nerve and epidermal growth factors induce the release of the Alzheimer amyloid precursor from PC 12 cell cultures. Biochem Biophys Res Commun 164: 664–670.

23. Miettinen PJ, Ustunov J, Ornio P, Gao R, Palgi J, et al. (2006) Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal beta-cell growth. Diabetes 55: 3299–3308.

24. Hart AW, Bazza N, Apelqvist A, Edlund H (2000) Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 408: 864–868.

25. Mashayekhi F, Mirzajani E, Najj M, Azari M (2010) Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease. J Clin Neurosci 17: 623–627.

26. Freude S, Schilbach K, Schubert M (2009) The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer’s disease: From model organisms to human disease. Curr Alzheimer Res 6: 213–223.

27. Kim B, Backus C, Oh S, Hayes JM, Feldman EL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150: 5294–5301.

28. Jolivalt CG, Hurford R, Lee CA, Duinaop W, Rockenstein E, et al. (2010) Type 1 diabetes exaggerates features of Alzheimer’s disease in APP transgenic mice. Exp Neurol 223: 422–431.

29. Taguchi A (2009) Vascular factors in diabetes and Alzheimer’s disease. J Alzheimers Dis 16: 839–864.

30. Sharief MK, Hannes R, Ciardi M (1991) Intrathecal immune response in patients with the post-polio syndrome. N Engl J Med 325: 749–753.

31. Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The function of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58(Suppl 1): I32–I39.

32. Taylor PC (2009) How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA? Nat Clin Pract Rheumatol 5: 126–127.

33. (1999) TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. the lenercept multiple sclerosis study group and the university of british columbia MS/MRI analysis group. Neurology 53: 457–465.

34. Chervonsky AV (1999) Apoptotic and effector pathways in autoimmunity. Curr Opin Immunol 11: 684–688.

35. Gatzka M, Walsh GM (2007) Apoptotic signal transduction and T cell tolerance. Autoimmunity 40: 442–452.

36. S Roriz-Filho J, Sa-Roriz TM, Rosset I, Camozzato AL, Santos AC, et al. (2009) (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792: 432–443.

37. Briesels GJ, Stackenborg S, Brummer E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5: 64–74.

38. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol 3: 169–178.

39. Hu Z, Snitkin ES, DeLisi C (2008) VisANT: An integrative framework for networks in systems biology. Brief Bioinform 9: 317–325.

40. Fisher, A R (1932) Statistical methods for research workers. Edinburgh: Oliver & Boyd.